Back to Feed
ClinicalTrials.gov|Clinical Trial
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Zhejiang University
Abstract
An open label, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301VT in subjects with advanced solid tumor. Phase: PHASE1 Status: ACTIVE_NOT_RECRUITING Conditions: Tumor Interventions: NW-301VT
Keywords
Tumor